surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Tirzepatide vs semaglutide: A new
Description
Semaglutide shelf life in the fridge is comparable to tirzepatide when stored properly
Never the freezer
You dont need to start training for a marathon, but even regular short walks and gradually doing more as your energy levels improve will make a difference
In the SURMOUNT trial (for obese or overweight non-diabetic patients), the average weight loss of patients in the high-dose (15mg) group was 20.9%, with a weight loss of approximately 22.5 kg
